The principal investigator of the study leading to approval said this new immunotherapy could be a "game changer" in bladder cancer. FDA last night approved nogapendekin alfa inbakicept-pmln (NAI) ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

Bacillus Calmette-Guérin (BCG) vaccine is the live attenuated vaccine form of Mycobacterium bovis used to prevent tuberculosis and other mycobacterial infections. Now, using zebrafish “avatars,” a ...

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B ...

Please provide your email address to receive an email when new articles are posted on . Patients with high-risk non-muscle-invasive bladder cancer who received durvalumab plus BCG had improved DFS.

Intravesical bacillus Calmette-Guérin (BCG) with and without isoniazid (INH) is associated with outcomes superior to those intravesical epirubicin in patients with intermediate- and high-risk Ta and ...

Discussion on current and future treatments for BCG-unresponsive HR NMIBC presented at ESMO 2023. This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD. Daneshmand ...

Despite the success of the PD-1 inhibitor sasanlimab in this setting, adding the PDL-1 inhibitor atezolizumab to intravesical BCG does not improve EFS in naïve patients with high-risk NMIBC, according ...

ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an alternative source of Bacillus Calmette-Guerin (BCG) to treat bladder cancer.

LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus ...

Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially support a resubmission of the sBLA ...